Niagen Bioscience
NAGE
62 hedge funds and large institutions have $15M invested in Niagen Bioscience in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 28 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.3% less ownership
Funds ownership: 22.2% → 17.91% (-4.3%)
11% less call options, than puts
Call options by funds: $48K | Put options by funds: $54K
17% less funds holding
Funds holding: 75 → 62 (-13)
41% less capital invested
Capital invested by funds: $25.3M → $15M (-$10.3M)
68% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 28
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$122K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.6K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$52.5K |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
+$45.1K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$44.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
-$1.25M |
| 2 |
Millennium Management
New York
|
-$906K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$510K |
| 4 |
Goldman Sachs
New York
|
-$498K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$251K |
NAGE Hedge Fund Activity: Q3 2022 in Review
62 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2022, worth a combined $15M — down 41% from $25.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NAGE and 3 opened new positions — a net loss of 13 holders — while 28 trimmed existing stakes and 9 added.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $122K. The largest seller was Yong Rong (HK) Asset Management, cutting an estimated $1.25M.
- 62 institutional investors held Niagen Bioscience (NAGE) as of Q3 2022, down from 75 in Q2 2022.
- Funds reported $15M of Niagen Bioscience stock for Q3 2022, down 41% quarter-over-quarter.
- 3 funds opened new Niagen Bioscience positions in Q3 2022 and 16 closed out, a net change of -13 holders.
- The largest Niagen Bioscience buyer in Q3 2022 was Royal Bank of Canada, an estimated $122K added.
- The largest Niagen Bioscience seller in Q3 2022 was Yong Rong (HK) Asset Management, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2022.